SEC v. Nutra Pharma Corp. et al (unregistered distributions, 2018)
Settled
Checked against the primary document on October 4, 2026. The library's summary, tags and figures for this record were compared with the regulator's own document by an AI model (Claude) following written instructions, with sampled and disputed records read a second time. No lawyer has reviewed them. A checked record can still contain errors, and checked does not mean endorsed. See how we check records or report a correction.
In September 2018 the SEC sued Nutra Pharma, its CEO Rik Deitsch and consultant Sean McManus over allegedly misleading press releases and unregistered stock distribution. After a partial summary judgment in 2022, consent judgments followed in March to August 2024, with combined disgorgement of about $570,000, interest of about $65,000 and penalties of $135,500.
The record
| Agency | SEC |
|---|---|
| Release number | LR-24295 |
| Date filed | 2018-09-28 |
| Date resolved | 2024-08-28 |
| Status | settled |
| Asset class | equities |
| Criminal parallel | No |
| Bars imposed | penny stock bar, officer-and-director bar, conduct-based injunction |
| Defendants | Nutra Pharma Corp. ; Rik Deitsch ; Sean McManus |
| Cited as charged or alleged | Exchange Act s.10(b) and Rule 10b-5 ; Exchange Act s.13(a) ; Exchange Act s.13(d) and 13(g) ; Exchange Act s.15(a) ; Exchange Act s.16(a) ; Exchange Act s.9(a)(2) ; Securities Act s.17(a) ; Securities Act s.5 |
| Techniques | Unregistered distributions |
What was ordered
- Civil penalty
- $136k
- Disgorgement
- $570k
- Prejudgment interest
- $64.9k
- Total relief
- $771k
- Alleged gain
- —
What is alleged to have happened
On September 28, 2018 the SEC filed a complaint in the Eastern District of New York against Nutra Pharma Corp., its CEO Rik Deitsch and consultant Sean McManus. It alleges that six press releases misled investors about the company's cobra venom business while it and Deitsch engaged in an unregistered distribution of its stock to retail investors, that Deitsch traded to prop up the price, and that McManus misled investors while acting as an unregistered broker. These are allegations. The record previously showed the defendants as 'Nutra Pharma Corp. et al'.
This library tags the matter as unregistered distributions, based on the conduct the document describes. The tagging is ours, not the regulator's: agencies charge statutory provisions, not technique names.
Three SEC releases show how the case ended for all three defendants. On 31 August 2022 the court granted the SEC summary judgment on some registration and reporting claims against Nutra Pharma and Deitsch. In March 2024 it entered partial consent judgments, and on 13 May 2024 final consent judgments against Deitsch ($44,046.28 disgorgement, $5,013.49 interest, $30,000 penalty, with officer-and-director and penny stock bars) and McManus ($5,500 disgorgement, $625.03 interest, $5,500 penalty, two-year penny stock bar). On 28 August 2024 the court entered a final consent judgment against the company for $520,940 in disgorgement, $59,295.05 in interest and $100,000 in penalties. The money fields sum all three, and they consented without admitting or denying the allegations. The releases mention no criminal case.
For the regulator's own account of the facts, read the primary document linked above. This page deliberately summarises the structured record rather than reproducing the release.
What technique is this, and how does it work?
This action is tagged with one technique in our taxonomy. The tagging is ours: regulators charge statutory provisions, not technique names, so the mapping is an editorial judgement described in our editorial policy.
- Unregistered distributions — see how it works, what statute it engages, and every other action tagged the same way.
Timeline
- 2018-09-28 Litigation release published
- 2022-08-31 Court grants SEC partial summary judgment against Nutra Pharma and Deitsch
- 2024-05-13 Final consent judgments entered against Deitsch and McManus
- 2024-08-28 Final consent judgment entered against Nutra Pharma
Primary documents
Everything on this page derives from the documents below. Where our summary and the primary document disagree, the primary document is right.
- SEC litigation release
- SEC litigation release LR-25510 (summary judgment)
- SEC litigation release LR-26007 (Deitsch, McManus)
- SEC litigation release LR-26088 (Nutra Pharma)
Same matter
The library links these 4 records because they appear to concern one matter: the same lead defendant, an overlapping technique tag and close filing dates, or a shared court docket or a release that cites the other. Records are listed by date filed.
| Date filed | Agency | Record | Status |
|---|---|---|---|
| 2018-09-28 | SEC | SEC v. Nutra Pharma Corp. et al (unregistered distributions, 2018) | Settled |
| 2022-09-16 | SEC | SEC v. Nutra Pharma Corp. et al (unregistered distributions, 2022) | Judgment entered |
| 2024-05-15 | SEC | SEC v. Nutra Pharma Corp. et al (unregistered distributions, 2024) | Judgment entered |
| 2024-08-30 | SEC | SEC v. Nutra Pharma Corporation, et al. (unregistered distributions, 2024) | Judgment entered |
Related actions
Other actions in the library sharing at least one technique tag with this one.
| Action | Agency | Filed | Technique | Penalty | Status |
|---|---|---|---|---|---|
| SEC v. Zachary Miller (unregistered distributions, 2026) | SEC | 2026-03-05 | Unregistered Distributions | — | settled |
| SEC v. David Hudzik (unregistered distributions, 2025) | SEC | 2025-12-23 | Unregistered Distributions | $70k | judgment |
| SEC v. Ongkaruck Sripetch and others (pump and dump, 2025) | SEC | 2025-06-20 | Pump And Dump , Unregistered Distributions | $204k | judgment |
| SEC v. Peter Scalise III and The3rdBevco Inc. (unregistered distributions, 2025) | SEC | 2025-06-17 | Unregistered Distributions | $236k | settled |
| SEC v. Investview, Inc. (unregistered distributions, 2025) | SEC | 2025-01-17 | Unregistered Distributions | $375k | settled |
| SEC v. Tai Mo Shan Limited (unregistered distributions, 2024) | SEC | 2024-12-20 | Unregistered Distributions | $36.7m | settled |